Disruption of Fnip1 Reveals a Metabolic Checkpoint Controlling B Lymphocyte Development

Heon Park,1 Karen Staehling,2,5 Mark Tsang,1 Mark W. Appleby2,6 Mary E. Brunke2,7 Daciana Margineantu,3 David M. Hockenbery,3 Tania Habib,1 H. Denny Liggitt,1 George Carlson,4 and Brian M. Iritani1,*

1The Department of Comparative Medicine, University of Washington, Seattle, WA 98195-7190, USA
2Celltech R & D, Inc., Bothell, WA 98021, USA
3Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
4The McLaughlin Research Institute, Great Falls, MT 59405, USA
5Present address: Stowers Institute for Medical Research, Kansas City, MO 64110, USA
6Present address: Novo Nordisk Inflammation and Research Center, Seattle, WA 98102, USA
7Present address: Institute for Systems Biology, Seattle, WA 98109, USA
*Correspondence: biritani@uw.edu
DOI 10.1016/j.immuni.2012.02.019

SUMMARY

The coordination of nutrient and energy availability with cell growth and division is essential for proper immune cell development and function. By using a chemical mutagenesis strategy in mice, we identified a pedigree that has a complete block in B cell development at the pre-B cell stage resulting from a deletion in the Fnip1 gene. Enforced expression of an immunoglobulin transgene failed to rescue B cell development. Whereas essential pre-B cell signaling molecules were activated normally in Fnip1-null pre-B cells, the metabolic regulators AMPK and mTOR were deregulated, resulting in excessive cell growth and enhanced sensitivity to apoptosis in response to metabolic stress (pre-B cell receptor crosslinking, oncogene activation). These results indicate that Folliculin-interacting protein 1 (Fnip1) is vital for B cell development and metabolic homeostasis and reveal a metabolic checkpoint that may ensure that pre-B cells have sufficient metabolic capacity to support division, while limiting lymphomagenesis caused by deregulated growth.

INTRODUCTION

The development of all metazoan organisms involves the strict coordination of cell growth, apoptosis, division, and differentiation. During B lymphocyte development, these processes are carefully linked to an orchestrated series of “checkpoints” that ensure that mature B cells can mount an immunogenic response against foreign antigens, without reacting against self. The earliest committed B cell progenitor (pro-B cell) is defined by having its immunoglobulin (Ig) genes in germline (unrearranged) configuration. The Ig heavy (IgH) chain gene segments rearrange first, and after successful in-frame VH-to-DHJH juxtaposition, the IgH chain “µ” pairs with surrogate light chain chaperones J5 and Vpre-B and signal transducing Igα and Igβ chains, as a component of the pre-B cell receptor (pre-BCR) complex on the surface of pre-B cells. The pre-BCR complex then signals pre-B cells to stop VH-to-DHJH rearrangement of the other IgH allele (a process called “allelic exclusion”), proliferate (synergistically with IL-7 receptor stimulation), start IgL chain (κ and λ) gene transcription and rearrangement (Vl-Jκ), and mature. After in-frame IgL chain rearrangement, the IgH and IgL chains pair to form IgM on the surface of immature B cells, at which point B cells with low self-reactivity exit the BM and migrate to peripheral lymphoid tissues, where development continues (see Goodnow et al., 2005, for review).

The importance of particular signaling proteins in pre-B cell development has been demonstrated through a series of biochemical and gene-targeting studies in mice (see Hendriks and Middendorp, 2004; Herzog et al., 2009, for review). For example, formation of the pre-BCR results in activation of the Ssc family protein tyrosine kinases (Ptk) Fyn, Lyn, and Blk, which phosphorylate membrane-bound Igα and Igβ on their immunoreceptor tyrosine-based activation motifs (ITAMs). This results in the activation and recruitment of the Syk Ptk, which activates the Ras-Raf signaling pathway and phosphorylates the adaptor protein SLP-65 (also known as BLNK). Phosphorylated SLP-65 then forms a signaling module that recruits and activates multiple pathways including phosphatidylinositol 3-kinase (PI3K) and the Tec family Ptk Btk and Tec, which activate PLCγ1/2 and ultimately Ca2+ flux. These events altogether lead to activation of essential transcriptional mediators including Erk, Myc (Habib et al., 2007), IRF-4/8, Foxo1, and NF-κB (see Herzog et al., 2009; Kurokoshi et al., 2010, for review).

In this study, we utilized a phenotype-driven “reverse-genetic,” recessive ethylnitosourea (ENU) mutagenesis strategy in mice to discover genes involved in immune cell development and function (see Appleby and Ramsdell, 2003; Cook et al., 2006, for review). In the course of this program, we identified a pedigree (denoted LPAB.1) that selectively lacks B cells in peripheral blood. By genome scanning, the B cell immunodeficiency phenotype was mapped to a noncoding deletion in the Fnip1 gene, which encodes for the 160 kDa protein Folliculin interacting protein-1 (Fnip1) (Baba et al., 2006). Although the biological functions of Fnip1 and the related Fnip family member Fnip2 (Hasumi et al., 2008; Takagi et al., 2008) are unknown, both molecules interact with Folliculin and AMP kinase (Baba et al., 2006).
Generation of RESULTS production, while protecting the host against excessive growth adequately equipped to fuel clonal expansion and antibody which we hypothesize may ensure that mature B cells are expressed in thymocytes, neither showed regulated expression during B cell development, reaching maximal levels in immature

A

WT

LPAB.1

B220

CD3ε

Peripheral blood

10^0 10^1 10^2 10^3 10^4

100 101 102 103 104

Figure 1. LPAB.1 Mice Lack Peripheral B Cells and Have a Deletion in the Fnip1 Gene
(A) Flow cytometric analyses of peripheral blood samples from LPAB.1 and WT mice revealed the absence of B220⁺ B cells, whereas CD3ε⁺ T cells were represented normally.

(B) A PCR genotyping strategy was designed with oligonucleotides spanning the 32 bp deleted region in the Fnip1 gene. Shown is an ethidium-stained acrylamide gel containing PCR products amplified from WT, Fnip1⁺/-, and Fnip1⁻/- genomic DNA.

(C) Representative immunoblot showing the absence of Fnip1 protein in testis, bone marrow cells (BM), and blood from Fnip1⁻/- mice relative to WT littermates.

 Fnip1 Is Essential for B Cell Development

2006; Hasumi et al., 2008), a highly conserved master sensor and regulator of cellular metabolism (see Towler and Hardie, 2007, for review). In response to low energy (low ATP, high AMP), AMPK is activated by phosphorylation at threonine 172 by LKB1 kinase. Activated AMPK then stimulates ATP production by increasing glucose uptake, stimulating mitochondrial biogenesis, and increasing glycolysis and oxidative phosphorylation (by inducing expression of the PGC1α and PPAR-γ transcription factors). AMPK also decreases ATP consumption by inhibiting mammalian target of rapamycin (mTOR)-driven cell growth, in part by phosphorylating and activating the mTOR inhibitor tuberous sclerosis protein 2 (TSC2) (Inoki et al., 2003) and by phosphorylating and inactivating the mTOR-positive regulatory protein Raptor (Gwinn et al., 2008). Our studies indicate that Fnip1 maintains metabolic homeostasis in developing B cells and reveal a metabolic “checkpoint” during B cell development, which we hypothesize may ensure that mature B cells are adequately equipped to fuel clonal expansion and antibody production, while protecting the host against excessive growth and transformation.

RESULTS

Generation of Fnip1-Null Mice by ENU Mutagenesis
We screened G3 mice from a large-scale ENU mutagenesis project for recessive mutations leading to specific immunodeficiencies. By utilizing flow cytometry to assess the representation of immune cells in peripheral blood, we identified the LPAB.1 pedigree based on an absence of B lymphocytes (Figure 1A), whereas myeloid and T cells were represented normally. By mapping affected G3 animals via positional cloning strategies, the LPAB.1 mutation was localized to a 1.7 Mb interval on chromosome 11. We sequenced candidate genes and identified a 32 bp deletion in exon 9 of a putative gene (A730024A03Rik), which resulted in the generation of a premature stop codon at residue 293 (Figure S1A available online). The product of A730024A03Rik was subsequently identified as the murine homolog of Fnip1 (Baba et al., 2006). PCR analysis confirmed that the deletion (Figure 1B) tracked with the B cell immunodeficiency and immunoblotting with α-Fnip1 revealed the absence of Fnip1 protein in tissues from LPAB.1 (Fnip1⁻/-) mice (Figure 1C). Fnip1⁻/- mice were viable and fertile but exhibited several additional phenotypes relative to wild-type (WT) littermates, including alterations in skeletal muscle (which appeared deep red as a result of high mitochondria content), increased liver glycogen content, and hypertrophic cardiomyopathy (data not shown). Taken together, these results indicate that the lack of B cells in LPAB.1 mice maps to a deletion in the Fnip1 gene, which results in the absence of Fnip1 protein.

Fnip1 Is Expressed in Multiple Tissues
We examined the expression of Fnip1 in 25 different normal mouse tissues (Park et al., 2008) by real-time PCR. We found that Fnip1 was highly expressed in testes, kidney, skeletal muscle, liver, heart, and embryo, in addition to thymus, spleen, and bone marrow (BM) (Figure S1B). Fnip1 was equally expressed in FACS-sorted B lineage cells throughout B cell development, whereas Fnip2 expression sharply increased during B cell development, reaching maximal levels in immature B cells (Figure S1C). Although both Fnip1 and Fnip2 were expressed in thymocytes, neither showed regulated expression during T cell development (Figure S1D). Transfection of Flag-tagged Fnip1 into the WEHI B cell line indicated that Fnip1 protein resides in the cytoplasm (Figure S1E), as was previously...
shown in a kidney cell line (Baba et al., 2006). These results collectively suggest that Fnip1 is normally expressed in multiple tissues including hematopoietic cells and encodes for a cytoplasmic protein in B cells.

**Absence of Fnip1 Blocks B Cell Development at the Large, Pre-B Cell Stage**

To examine where loss of Fnip1 blocks B cell development, total BM cells and splenocytes were stained with antibodies against proteins that are differentially expressed during B cell development (Figure 7D). Analysis of Fnip1−/− BM revealed a complete block at the B220+CD43+CD25+MHCIId− large pre-B cell stage (Figure 2A), which resulted in the absence of mature B cells bearing IgM, CD21, and CD23 in the BM and spleen (Figures 2A and 2B). Fnip1−/− mice also lacked “B1” B lymphocytes, which represent a subset of B cells that are found in the peritoneal and pleural cavities (Figure 2C; Hardy and Hayakawa, 2001). Fnip1−/− mice failed to produce serum Igs of all isotypes after immunization with keyhole limpet hemocyanin (KLH) (Figure 2D). Intracellular (IC) flow cytometric analyses indicate that Fnip1−/− BM B cells contain IC IgM “μ” protein but lack IC IgL “κ” (Figure 2E). These results suggest that loss of Fnip1 results in a complete block in B cell development at the large pre-B-to-small pre-B cell transition mediated by formation of the pre-BCR (Figure 7D; Hardy and Hayakawa, 2001).

We next examined the ability of Fnip1−/− pre-B cells to divide and survive in the presence or absence of the growth factor IL-7. CFSE analyses indicated that Fnip1−/− pre-B cells divide equally well as WT pre-B cells in vitro in response to IL-7 (Figure 2F), whereas the proliferation of Rag2−/− pro-B cells is blunted as a result of the absence of pre-BCR formation, which normally synergizes with IL-7 for maximal proliferation (Fleming and Paige, 2002). Fnip1−/− pre-B cells also divided equally well as WT pre-B cells in vivo, based on equivalent incorporation of BrdU after 48 hr (Figure 2B). Fnip1−/− B220+CD43+IgM− pre-B cells, but not B220+CD43+ pre-B cells, exhibited significantly decreased viability relative to WT pre-B cells (Figure 2F). Antibody-mediated crosslinking of IgL, which mimics pre-BCR crosslinking, induced apoptosis of Fnip1−/− pre-B cells and failed to stimulate pre-B cell development, whereas Rag2−/− pro-B cells were induced to mature based on downregulation of CD43 (Figure 2G) and upregulation of CD25 (Kouro et al., 2001). Relative to WT pre-B cells, Fnip1−/− pre-B cells expressed normal mRNA levels of the antipapoptotic molecule Bcl2 and slightly decreased levels of the proapoptotic molecule Bim (Figure S2C) and were equally sensitive to apoptosis in response to the protein kinase inhibitor staurosporine (Figure S2D) or Fas crosslinking (Figures S2E), suggesting that apoptosis is relatively specific to activation. These results suggest that Fnip1−/− pre-B cells fail to mature in response to pre-BCR signals, whereas proliferative signals emanating from the pre-BCR and the IL-7 receptor are transmitted relatively normally.

**Enforced Expression of IgH, IgL, or IgM Fails to Rescue B Cell Development in Fnip1−/− Null Mice**

We next tested whether the experimental provision of rearranged IgH and/or IgL chains in Fnip1−/− mice could overcome the arrest in B cell development. Fnip1−/− and Rag2−/− (control) mice were crossed with IgMHEL mice, which carry a rearranged IgH chain “knockin” allele (denoted IgHHEL) and a separate IgL “κ” transgene (denoted IgLHEL), which together encode surface IgM specific against hen egg lysozyme (HEL) protein (Allen et al., 2007). We assessed whether IgHHEL, IgLHEL, or IgHHEL plus IgLHEL (IgLHEL) could stimulate B cell development in Fnip1−/− and Rag2−/− control mice. Expression of a rearranged IgH chain (IgHHEL), which mimics pre-BCR expression, efficiently drove B cell maturation in Rag2−/− mice based on downregulation of CD43 upregulation of CD25 and MHC II (Figure S3A), and a reduction in cell size (data not shown). In contrast, IgHHEL was unable to stimulate B cell maturation in Fnip1−/− mice, suggesting that pre-BCR signaling is impaired. Similarly, expression of a rearranged IgL chain (IgLHEL-Tg), which pairs with endogenous Fnip1−/− IgH chains to form surface IgM, also failed to stimulate Fnip1−/− pre-B cell progenitors to mature (Figures S3B–S3D). Remarkably, live-gated Fnip1−/− B cell progenitors that expressed both IgHHEL and IgLHEL (IgLHEL) still failed to mature (Figure 3A) and migrate to the periphery (Figure 3B) despite high-level IgM expression, which potently drove B cell development and migration to the periphery in Rag2−/− mice. Fnip1−/− IgMHEL BM B cells exhibited a “tolerant-like” phenotype consisting of CD62L+ B220+IgM+ and were more sensitive to apoptosis in response to anti-IgM (data not shown). These results demonstrate that Fnip1 is absolutely required for pre-BCR-mediated B cell differentiation and suggest a potential role for Fnip1 in BCR-mediated maturation and survival.

**Allelic Exclusion of the Ig Heavy Chain Occurs Normally in the Absence of Fnip1**

It has previously been shown that expression of a rearranged IgH chain in pro-B cells mimics pre-BCR formation, resulting in suppression of endogenous IgH chain gene rearrangement (allelic exclusion) (Nussenzweig et al., 1987). Therefore, we utilized IgMHEL mice to ask whether expression of IgHHEL and IgLHEL, which together form IgM of the “α” isotype (IgMα), would extinguish expression of endogenous μ chains (IgMβ) in Fnip1−/− B cells. As shown in Figure 3C, WT C57BL6 mice express surface IgMβ, whereas Fnip1−/− mice lack IgM expression because of the absence of IgL chains. Expression of IgLHEL-Tg in Fnip1−/− mice restored surface expression of IgMβ. However, when Fnip1−/− mice were bred to IgHHEL/IgLHEL mice (IgMβ), all B cells expressed IgMα and not endogenous IgMβ, indicating that signals delivered from the IgMHEL efficiently extinguished rearrangement and expression of the endogenous IgMα in Fnip1−/− mice.

**Impaired B Cell Development in Fnip1−/Null Mice Is Cell Autonomous**

To determine whether the defects in B cell development are autonomous to Fnip1−/− pre-B cells, we transferred total BM cells from WT (CD45.1+), Fnip1−/− (CD45.2+), or mixed WT and Fnip1−/− cells into lethally irradiated Rag2−/−Ii2rg−/− (recombinase activating gene 2/common γ chain double null) hosts (CD45.2+) (Garcia et al., 1999). The development of donor hematopoietic cells were analyzed ~15 weeks after transplantation. As shown in Figure S6, Rag2−/−Ii2rg−/− completely lacked all lymphocytes as a result of complete blocks in B and T cell development.
Figure 2. Loss of Fnip1 Results in a Complete Block in B Cell Development at the Pre-B Cell Stage
(A–C) BM cells (A), splenocytes (B), and peritoneal cells (C) derived from Fnip1−/− and WT mice were stained with fluorescent-conjugated antibodies and analyzed by flow cytometry. Shown are representative histograms (of eight mice/group). B1a, B1b, and B2 refer to types of B cells (Hardy and Hayakawa, 2001).

Please cite this article in press as: Park et al., Disruption of Fnip1 Reveals a Metabolic Checkpoint Controlling B Lymphocyte Development, Immunity (2012), doi:10.1016/j.immuni.2012.02.019
immunity

Fnip1 is Essential for B Cell Development

development at the pro-B and the CD4+ CD8− cell stages, respectively. Transfer of WT BM cells rescued the development of B220+IgM+ B, GR1+ myeloid, and CD4+ and CD8+ T cells. In contrast, transfer of Fnip1−/− BM rescued the development of CD4+ and CD8+ T cells but failed to restore the development of Fnip1−/− B cells. Transfer of a 1:1 mixture of CD45.1+ WT:CD45.2+ Fnip1−/− BM cells rescued the development of both WT and Fnip1−/− T cells and GR1+ myeloid cells, but only WT CD45.1+ (CD45.2+) IgM+ B cells. These results indicate that the defect in the development of Fnip1−/− B cells is cell autonomous and is not due to a defective BM environment or secretion of a B cell inhibitory factor.

retroviral expression of Fnip1 rescues B cell development in Lpab1 mice

to confirm that the absence of Fnip1 is directly responsible for the Lpab1 phenotype, we infected lineage-negative (Lin−) BM cells from Fnip1−/− mice with empty MSCV retrovirus or with MSCV containing full-length Fnip1 cDNA and transplanted the cells into Rag2−/−/Ii2rg−/− mice. Empty MSCV-infected Fnip1−/− BM cells failed to restore B cell development after transplant into Rag2−/−/Ii2rg−/− hosts, while CD4+ and CD8+ T cells are efficiently rescued to normal levels, confirming successful engraftment of Fnip1−/− donor HSCs (Figure S7A). In contrast, transfer of MSCV-Fnip1-infected Fnip1−/− BM also rescued the development of conventional B220+IgM+ B cells and CD5− cells from Fnip1−/− mice relative to WT mice (Figure 4A). Flow cytometry and transmission electron microscopy (EM) analyses further revealed that Fnip1−/− B cell progenitors exhibited increased labeling with the mitochondrial dye Mitotracker green relative to WT B cell progenitors (Figure 4B) and contained significantly increased numbers of mitochondria (Figure 4C). Fnip1−/− B cell progenitors took up the fluorescent deoxyglucose analog 2-NBDG more effectively than did WT pre-B cells in response to IL-7 (Figure 4D). These results confirmed that the upregulated AMPK and PGC-1α gene signature correlates with increased AMPK and PGC1α function in Fnip1-null pre-B cells. To determine whether the upregulated mTOR gene signature correlated with increased cell growth, we examined mTOR activation and cell size by flow cytometry. We found that relative to WT pre-B cells, Fnip1−/− pre-B cells exhibited increased intracellular phospho-S6 ribosomal protein (pS6R) (Figure 4E), which is a downstream mediator of mTOR signaling that stimulates ribosome biogenesis and translation and are significantly larger in size relative to WT pre-B cells and Rag2−/− pro-B cells (Figure 4F). These results collectively suggest that loss of Fnip1 results in parallel increases in catabolic metabolism and mTOR-mediated anabolic metabolism, two normally antagonistic energy-regulating processes that typically occur separately.

Fnip1 Controls the Ability of AMPK to Inhibit mTOR-Mediated Cell Growth

Although the cellular and molecular functions of Fnip1 are unknown, both Fnip1 (Baba et al., 2006) and Fnip2 (Hasumi et al., 2008; Takagi et al., 2008) have been shown to interact with pre-BCR signaling and metabolism, which is an important checkpoint controlling B lymphocyte development. We assessed the presence and activation of known pre-BCR

See also Figure S2.
Figure 3. Enforced Expression of Ig Heavy and Ig Light Chains Fail to Drive B Cell Development in Fnip1-Null Mice, whereas Allelic Exclusion Occurs Normally

(A and B) Total BM cells (A) and splenocytes (B) from WT, Rag2−/−, Rag2−/− IgHHELIgLHEL, Fnip1−/−, and Fnip1−/− IgHHELIgLHEL mice were analyzed by flow cytometry utilizing the indicated fluorescent-conjugated antibodies. IgMHEL stimulates the development of Rag2−/− pro-B cells but fails to stimulate the maturation of Fnip1−/− pre-B cells. Representative histograms of five mice per group are shown.

(C) Allelic exclusion occurs normally in Fnip1−/− mice. Total BM cells from the indicated mice were stained with fluorescent-conjugated α-B220 and HEL (top) or α-IgMa and α-IgMb (bottom). Shown are representative flow cytometric histograms from four mice per group.
Figure 4. Loss of Fnip1 Results in Metabolic Dysregulation in Pre-B Cells Defined by Increased Expression of AMPK and mTOR-Regulated Genes, Increased Mitochondrial Biogenesis, and Increased mTOR-Mediated Cell Growth

(A) Purified pre-B cell cDNA from Fnip1<sup>−/−</sup> and WT mice were subjected to real-time PCR specific for the indicated genes. Bars indicate means ± SEM of three mice per group. *p values are shown.

(B) Increased mitochondria in Fnip1<sup>−/−</sup> pre-B cells. Fnip1<sup>−/−</sup> and WT BM cells were stained with α-B220, α-CD43 plus the mitochondrial dye MitoTracker green. Shown is a representative flow cytometric histogram (n = 3 mice per group) of gated B220<sup>+</sup>CD43<sup>+</sup> cells.

(C) Transmission electron micrographs were obtained on FACS-sorted pre-B cells from three WT and three Fnip1<sup>−/−</sup> mice. Left: Representative high-power images (20,000×). Right: The number of mitochondria per field were enumerated in the cytoplasmic compartment for 8 WT and 17 Fnip1<sup>−/−</sup> pre-B cells. Bars indicate means ± SEM; *p < 0.00006.

(D) Increased glucose uptake in Fnip1<sup>−/−</sup> pre-B cells. Total BM cells were cultured in media, IL-7, IL-3, or insulin at the indicated concentrations for 48 hr. 2-NDBG was added for the last 3 hr. Shown is bar graph (n = 3 per group for IL-7, n = 2 per group in triplicate for IL-3, insulin) showing the relative fluorescence intensity of B220<sup>+</sup>IgM<sup>+</sup> gated cells as assessed by flow cytometry. Error bars indicate mean ± SEM. *p values are shown.

(E) Fnip1<sup>−/−</sup> and WT BM cells were stained with α-B220, α-CD43, and intracellular pS6R. Shown is a representative histogram.

(F) Shown is a representative forward-light scatter (FSC) histogram overlay comparing the size of gated B220<sup>+</sup>IgM<sup>+</sup> pro-B and pre-B cells from WT, Rag2<sup>−/−</sup>, and Fnip1<sup>−/−</sup> mice.

See also Figure S4.
AMPK with AICAR inhibited S6 kinase-induced phosphorylation of S6 ribosomal protein (S6R) in WT pre-B cells (indicative of decreased mTOR function), activation of AMPK failed to inhibit phosphorylation of S6R in Fnip1−/− pre-B cells (Figure 5B), which paralleled our findings with flow cytometry (Figure 4E). AMPK appeared to phosphorylate (and presumably inhibit) the mTOR partner Raptor normally in the absence of Fnip1 (Gwinn et al., 2008). Akt (a positive regulator of mTOR) was phosphorylated normally at the Thr308 and Ser473 activation sites (Sengupta et al., 2010) in the absence of Fnip1 (Figures S5A and SSC). These results collectively suggest that Fnip1 is not required for activation of AMPK or AMPK-mediated catabolism but is important for AMPK to inhibit mTOR.

**Loss of Fnip1 Increases Sensitivity to Nutrient Deprivation-Induced Apoptosis and Developmental Arrest**

Because Fnip1−/− pre-B cells exhibited increased mTOR activation and cell growth (which consumes nutrients), even in the presence of activated AMPK (low energy), we reasoned that perhaps Fnip1 loss results in a “nutrient and energy deficit,” which may trigger apoptosis or anergy in Fnip1−/− pre-B and Fnip1−/−IgMIEL B cells after pre-BCR or BCR crosslinking, when energy and nutrient demands increase sharply to accommodate cell division. First, we tested whether a “nutrient-rich” environment would increase survival of Fnip1−/− B cells by culturing BM cells or sorted pro-B cells from Fnip1−/− or WT mice in nutrient-rich media. Surprisingly, culture of total BM (Figure 6A) or sorted B220−CD43+ pre-B cells (Figure 6B and data not shown) in B cell growth media (10% fetal calf serum, 1% nonessential amino acids, 1% L-glutamine, 1% sodium pyruvate, 1% mercaptoethanol) rescued a small population of IgM+ B cells, which could be rescued in a dose-dependent manner by the addition of IL-7/SCF/Flt3 ligand (Figures 6A and 6B) and was associated with increased intracellular IgM protein expression (data not shown).

We next determined which nutrients are most critical for the development of IgM+ Fnip1−/− B cells. We found that culturing pre-B cells in glucose- or glutamine-free media prevented the emergence of Fnip1−/− IgM+ B cells at concentrations where the emergence of WT IgM+ B cells were relatively unaffected (Figure 6B and data not shown). Furthermore, removal of essential amino acids (EAA) significantly inhibited the development of Fnip1−/− IgM+ B cells, which could be rescued in a dose-dependent manner by the addition of EAAs (Figure 6C). Administration of oligomycin, which blocks ATP synthase and oxidative phosphorylation, also inhibited the emergence of Fnip1−/− IgM+ B cells at concentrations that do not affect the development of WT IgM+ B cells (Figure 6D).

To examine why Fnip1−/− B cells might be in metabolic deficit, we analyzed pre-B cell metabolism on FACS-sorted pre-B cells with the Seahorse Extracellular Flux Analyzer. Fnip1−/− pre-B cells have decreased basal oxygen consumption rate (OCR), which is a measure of oxidative phosphorylation (OXPHOS) (Figure 6E). OCR and extracellular acidification rate (ECAR), which is a measure of glyceralysis, could be restored to a hypermetabolic state in Fnip1−/− pre-B cells by the addition of IL-7, which

---

**Figure 5. Dysregulated mTOR Signaling in Fnip1−/− Pre-B Cells**

(A) B cell progenitors from Rag2−/− and Fnip1−/− mice were activated with α-Igβ at the indicated time points. Immunoblots were probed with antibodies against total phosphotyrosine.

(B) Fnip1−/− and WT mice were injected with the AMPK-activator AICAR. Total BM cells from untreated or AICAR-treated mice were isolated 18 hr post-injection and B220−CD43+ cells were FACS sorted. Immunoblots (representative of 3–4 experiments) were performed with the indicated antibodies. See also Figure S5.
stimulates glucose uptake (Figure 4D) and restores energy balance (Figures 6E; Rathmell et al., 2001). Fnip1−/− pre-B cells also exhibited increased sensitivity to 2-deoxyglucose (glycolysis inhibitor) and etomoxir (fatty acid oxidation inhibitor) (Figure 6F), which correlated with decreased basal ATP levels relative to WT pre-B cells (Figure 6G).

To examine whether increased PPARγ or dysregulated mTOR (Figure S5D) are responsible for impaired B cell development in Fnip1−/− mice, we first cultured BM cells from Fnip1−/− mice in B cell growth media with or without different concentrations of the specific PPARγ-inhibitor GW9662 (Bendixen et al., 2001). We found that inhibiting PPARγ did not rescue nutrient-mediated

Figure 6. Loss of Fnip1 Alters Metabolic Homeostasis and Sensitizes Pre-B Cells to Nutrient and IL-7 Restriction

(A) In vitro nutrient supplementation partially rescues IgM expression in Fnip1−/− B cell progenitors. Total BM derived from WT and Fnip1−/− mice were grown in complete B cell growth media for 0, 24, or 48 hr in the presence or absence of growth factors (IL-7, SCF, and Flt-3L). Cells were analyzed by a flow cytometry with fluorescent-conjugated α-B220 and α-IgM. Bars represent the means ± SEM from six mice per group.

(B) Depletion of glucose or glutamine inhibits the development of Fnip1−/− pre-B cells in vitro. FACS-sorted B220loIgM−/− cells were grown in complete media in the presence or absence of growth factors, glucose, or glutamine for 48 hr. Cells were analyzed by a flow cytometry with fluorescent-conjugated α-B220 and α-IgM. Bars represent the means ± SEM from WT (n = 3) and Fnip1−/− (n = 6) mice.

(C and D) Total BM were cultured in complete media for 48 hr in the presence of (C) different amounts of essential amino acids (no aa, or 1, 2, or 4x aa) or (D) oligomycin (0, 1, 5, 10, 50 nM). Cells were analyzed by a flow cytometry with fluorescent-conjugated α-B220 and α-IgM. Bars represent the means ± SEM from WT (n = 4) and Fnip1−/− (n = 4) mice on gated B220lo populations.

(E and F) Oxygen consumption rate (OCR) and extracellular acidification (ECAR) were measured with a Seahorse Bioscience extracellular flux analyzer over the course of 150 min. FACS-sorted pro-/pre-B cells from Fnip1+/− and Fnip1−/− BM were cultured in the absence or presence of growth factors (10 ng/ml of IL-7 and SCF) for 24 hr prior to analyses.

(F) OCR and ECAR were then measured within 5 min of culture. Shown is the mean ± SEM from five mice per group. p values are shown.

(F) OCR were measured within 5 min of culture in the presence of 2-deoxyglucose (2-DG) or etomoxir (ETMX). Shown is the decrease in OCR after treatment relative to pretreatment baseline. Mean ± SEM (three mice per group).

(G) ATP levels from FACS-sorted WT (n = 3) and Fnip1−/− (n = 3) pre-B cells were determined with a luciferase assay. Mean ± SEM (three mice per group). p values are shown.
IgM expression in Fnip1−/− pre-B cells (Figure 7B), suggesting that increased expression of PPARγ (Figure 4A) may reflect an attempt to maintain energy balance in response to dysregulated mTOR. Likewise, activation of PPARγ in WT pre-B cells with the agonist troglitazone did not inhibit pre-B to immature B cell development, although the cells exhibited increased nonspecific apoptosis (Figure 7C). Injection of Fnip1−/− mice with the mTORC1-inhibitor rapamycin also failed to rescue B cell development in vivo. However, delivery of a combination of rapamycin and IL-7 (which increases glucose uptake) were sufficient to rescue the emergence of IgM+ cells in Fnip1−/− mice after 2 weeks (Figure 7D). These results collectively suggest that loss of Fnip1 results in excessive mTOR-mediated metabolite consumption, increased nutrient demand, impaired OXPHOS, and IL-7 “addiction,” which prevent the development of pre-B cells in response to nutrient stress and pre-BCR crosslinking.

**Fnip1 Deficiency Inhibits Pre-B Cell Transformation by c-Myc**

Because cancer cells have high metabolic demands, we hypothesized that disruption of Fnip1 might sensitize pre-B cells to oncogene-induced apoptosis. To test this hypothesis, we bred Fnip1−/− mice to mice that overexpress the c-Myc oncogene under control of the Ig heavy chain enhancer Eμ (TgNIlgHMyC) 22Bri [also known as Eμ-Myc]. Eμ-Myc transgenic mice typically develop pre-B cell lymphomas at around 8–30 weeks of age (Adams et al., 1985). As a control, we also bred Fnip1−/− mice to mice that overexpress the c-Myc oncogene associated with increased apoptosis of B220+CD43+ pre-B cells relative to Eμ-Myc Fnip1−/− pre-B cells (Figure 7C), whereas cell division was unaffected (data not shown). These results collectively demonstrate that Fnip1 is important for the generation of pre-B cell lymphomas induced by c-Myc.
**DISCUSSION**

Resting B lymphocytes respond to foreign pathogens by rapidly shifting from a quiescent state to a metabolically activated phenotype, characterized by massive increases in macromolecular synthesis necessary for cell growth, division, and eventually Ig synthesis (see Rathmell, 2004, for review). The inability to accommodate these demanding bioenergetic processes would result in dysfunctional B cells and an immunodeficient host. Conversely, deregulated cell growth could result in lymphomagenesis and the demise of the host. In this study, we utilized an ENU mutagenesis screen in mice to identify a new B cell immunodeficient strain, caused by a noncoding deletion in the *Fnip1* gene. Our studies suggest that Fnip1 normally acts as a molecular switch to permit pre-B cell differentiation and survival in response to adequate metabolic balance, while turning off cellular growth. Disruption of *Fnip1* results in metabolic imbalance, which triggers apoptosis in response to “metabolic stress” such as pre-BCR stimulation, nutrient deprivation, or oncogene activation. We hypothesize that this “metabolic checkpoint” may ensure that maturing B cells have adequate metabolic capacity to fuel clonal expansion and to produce Igls while also attenuating deregulated cell growth and transformation.

Our analysis of *Fnip1^−/−* B cell progenitors reveals that Fnip1 is very unique in how it interacts with known pre-BCR signaling pathways. First, enforced expression of potent IgM^HEL^ signaling complexes failed to rescue B cell development in *Fnip1^−/−* mice, indicating that Fnip1 is required for B cell development downstream of the pre-BCR (and perhaps the BCR as well). Whereas mice deficient in other signaling molecules including Src, Syk, and Tec family PTKs, the adaptor protein SLP-65, and the Ca^2+^ signaling molecules PLCγ1/2 and the p85 subunit of PI3K also exhibit impaired B cell development at the large pre-B cell stage (see Herzog et al., 2009, for review), we find that these pathways (as well as important transcriptional mediators) are expressed or activated normally in *Fnip1^−/−* pre-B cells after α-IgM crosslinking. A second unique feature of Fnip1 is that loss of Fnip1 blocks pre-BCR-induced differentiation, whereas pre-BCR-induced proliferation (synergistic with IL-7) and allelic exclusion of the IgH chain loci remain intact. This is in contrast to disruption of the membrane portion of IgH, Igκ and Igλ, or Syk and Zap70, which result in blocked proliferation, differentiation, and allelic exclusion (Kurosaki et al., 2010). A third unique feature is that loss of Fnip1 potently inhibits transformation and/or survival by Myc, whereas disruption of another pre-BCR signaling molecule Igκ (which also blocks B cell development at the pre-B cell stage) results in significantly accelerated Myc-induced transformation. These results collectively highlight that Fnip1 functions in a distinct manner from most of the known pre-BCR signaling molecules.

Fnip1 was cloned based on its interactions with Folliculin and AMPK in kidney cells (Baba et al., 2006) and was subsequently shown to interact with Fnip2. Here, we find that AMPK is activated normally in pre-B cells from *Fnip1^−/−* mice relative to WT mice. In addition, we find increased expression of essential AMPK-induced mitochondrial metabolic genes and increased glucose uptake and mitochondrial biogenesis in *Fnip1^−/−* pre-B cells. However, whereas AMPK activation in WT pre-B cells shuts down mTOR-mediated anabolic (ATP and bioprecursor-consuming) growth (Gwinn et al., 2008), AMPK fails to inhibit mTOR-mediated growth in *Fnip1^−/−* pre-B cells, which correlates with decreased energy balance (decreased ATP) and increased sensitivity to apoptosis after pre-BCR activation, nutrient or IL-7 deprivation, or oncogene activation. These results, combined with previous studies by Baba et al. (2006) in HEK cells, suggest that Fnip1 acts downstream of AMPK to help maintain “metabolic homeostasis” in B lineage cells during metabolic stress (see Figure S5D for model). Recent studies indicate that disruption of AMPK-activator LKB1 also inhibits pre-TCR-mediated T cell development (Tamás et al., 2010), and disruption of LKB1 in hematopoietic stem cells results in dysregulated mTOR, increased cell growth, and decreased survival of differentiated hematopoietic cells (Gan et al., 2010; Gurumurthy et al., 2010; Nakada et al., 2010). Similar to Fnip1 deficiency, hematopoietic cell development is not rescued by rapamycin alone, indicating that Fnip1 and LKB1 may function in both mTORC1-dependent and -independent manners. Indeed, B cell development in *Fnip1^−/−* mice can only be partially rescued by a combination of rapamycin (which inhibits mTORC1) and IL-7 (which stimulates glucose uptake and OXPHOS).

Whereas both *Fnip1* and *Fnip2* are expressed during B cell development in WT mice, only *Fnip2* is significantly regulated with expression peaking in immature B cells. In addition, *Fnip2* mRNA levels increase in *Fnip1-null* pre-B cells (data not shown). These results suggest that Fnip1 and Fnip2 may only be active as heterodimers, which would explain why Fnip2 does not compensate for the absence of Fnip1. Targeted disruption of the *Fnip2* gene in mice should shed light on this issue.

An important distinction between *Fnip1-null* pre-B cells, which exhibit increased mTOR activity, and other human diseases whereby mTOR is dysregulated is the absence of benign or malignant overgrowth. For example, mutations in *LKB1*, *PTEN*, *FLCN*, and *TSC1/2* result in deregulated mTOR and overgrowth (hamartoma) syndromes or cancer in humans (see Shackelford and Shaw, 2009, for review). In addition, loss-of-function mutations in the *PPKAG2* gene encoding the α subunit of AMPK result in familial cardiac hypertrophy and Wolf-Parkinson’s-White syndrome, overgrowth diseases characterized by cardiac hypertrophy and arrhythmias resulting from dysregulated mTOR (Arad et al., 2007). We find that loss of Fnip1 also results in cardiac hypertrophy and excessive growth of pre-B cells characterized by dysregulated mTOR. However, we have not observed transformation of any cell types including pre-B cells, and we find that loss of Fnip1 inhibits pre-B cell lymphomagenesis by the c-Myc oncogene, which potently drives transformation in part by increasing the metabolic capacity of cancer cells (see Dang et al., 2009, for review). Thus, our results suggest the existence of a “metabolic checkpoint” during B cell development, which inhibits the maturation and survival of pre-B cells that are “metabolically insufficient,” either because of mutations that disrupt energy- or bioprecursor-generating pathways and/or because of excessive energy or bioprecursor consumption. Inhibition of Fnip1 could provide a novel mechanism to limit the fuel necessary to support cancer cell metabolism (Vander Heiden et al., 2009), thus selectively sensitizing highly metabolic cancer cells for apoptosis in response to chemotherapy or metabolic stress.
**EXPERIMENTAL PROCEDURES**

**Mice**

VDJSHyHEL10 heavy chain knockin mice and HyHEL10 light chain transgenic mice were provided by J. Cyster (Allen et al., 2007). IgHm1C0, Tg[MyC](HyMc)22Bri, and Rag2<sup>−/−</sup> mice and Rag2<sup>−/−</sup>Il2r<sup>−/−</sup> mice were purchased from Jackson Laboratories and Taconic Farms. Inc. Fnp1<sup>−/−</sup> mice were screened and maintained by genomic PCR analysis after amplification with Fnp1 forward (5'-ACTTGTGCATTAGTTCTTCAGT-3') and reverse (5'-GCACAT CACATCTAGGAAACCC-3') oligonucleotides. Mice were housed under specific-pathogen-free conditions. Mouse procedures were approved by the Institutional Animal Care and Use Committees of Cellect R&D, Inc., and the University of Washington.

**Immunoblot Analysis**

Immunoblot analyses were performed as previously described (Iritani et al., 1997) with rabbit polyclonal antibodies specific for Fnp1 (anti-hFNIP1; Abcam, MA); β-Actin, Syk, Btk (Santa Cruz Biotech); Bnk, P-Tyr96 Bnk, Akt, P-Ser473 Akt, P-Thr308 Akt, P-Ser176/180IKK, P-S6R, BrdU, Annexin V, BP1, HSA, CD5, CD4, CD8, and Lysozyme and analyzed by flow cytometry as previously described (Habib et al., 2007). Mitochondrial staining was performed with MitoTracker green dye (Molecular Probes).

**Flow Cytometry and Cell Sorting**

BM, thymus, and spleen were stained with fluorescent-conjugated antibodies specific for CD5, B220, CD21, CD25, CD222.2, CD62L, IκB, CD23, CD43, Igk, Igk<sup>+</sup>, J5, Igl, pS6R, BrdU, Annexin V, BP1, HSA, CD5, CD4, CD8, and Lysozyme and analyzed by flow cytometry as previously described (Habib et al., 2007). Mitochondrial staining was performed with MitoTracker green dye (Molecular Probes).

**Cell Proliferation and Viability**

BM cells were labeled with CFSE and then cultured in the presence or absence of IL-7 (10 ng/ml) for 4 days. Cell division was determined by flow cytometry on gated B220<sup>+</sup> cells (Habib et al., 2007). BM cells were stained with α-B220, α-CD43, and 7AAD (Invitrogen) or α-mouse IgG HRP (Bio-Rad Laboratories), and 4G10 antibody (Upstate Biotech).

**Statistical Analysis**

Data were analyzed with the Student’s one- or two-tailed t test. Kaplan-Meier curve statistics were performed with Log-rank Mantel-Cox test. p < 0.05 were considered significant.

**ACCESSION NUMBERS**

The microarray data are available in the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds) under the accession number GSE37887.

**SUPPLEMENTAL INFORMATION**

Supplemental information includes Supplemental Experimental Procedures, seven figures, and one table and can be found with this article online at doi:10.1016/j.immuni.2012.02.019.

**ACKNOWLEDGMENTS**

This study was supported by the University of Washington Royalty Research Fund #4162, NIH K26RR024462, MMPC 09MC06, ITHS UL1RR05014, and P30 CA15704 grants to B.M.I. We thank J. Cyster for kindly providing IgM<sup>HEL</sup> and mice and J. Delrow and R. Basom for assistance with the microarray analyses. M.W.A. is an employee and shareholder of Novo Nordisk and is a former employee of ZyagenGenetics Inc. M.W.A., K.S., and M.E.B. are former employees of Cellect R&D, Inc. This work was supported in part by funding from Cellect R&D, Inc.


